Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPARγ
- 1 July 2019
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 286, 30-39
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (21591144, 20390259)
This publication has 45 references indexed in Scilit:
- Local proliferation dominates lesional macrophage accumulation in atherosclerosisNature Medicine, 2013
- Thiazolidinedione‐independent activation of peroxisome proliferator‐activated receptor γ is a potential target for diabetic macrovascular complicationsJournal of Diabetes Investigation, 2011
- Pioglitazone modulates the balance of effector and regulatory T cells in apolipoprotein E deficient miceNutrition, Metabolism and Cardiovascular Diseases, 2011
- Pioglitazone-Induced Reductions in Atherosclerosis Occur via Smooth Muscle Cell–Specific Interaction With PPARγCirculation Research, 2010
- Statins Activate Peroxisome Proliferator-Activated Receptor γ Through Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase–Dependent Cyclooxygenase-2 Expression in MacrophagesCirculation Research, 2007
- Macrophage-specific PPARγ controls alternative activation and improves insulin resistanceNature, 2007
- Pioglitazone induces apoptosis of macrophages in human adipose tissueJournal of Lipid Research, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- The effect of high glucose and PPAR-γ agonists on PPAR-γ expression and function in HK-2 cellsAmerican Journal of Physiology-Renal Physiology, 2004
- 15d-PGJ2 inhibits oxidized LDL-induced macrophage proliferation by inhibition of GM-CSF production via inactivation of NF-κBBiochemical and Biophysical Research Communications, 2004